Pneumocystis jirovecii pneumonia in HIV-uninfected, rituximab treated non-Hodgkin lymphoma patients

Rituximab is associated with a higher incidence of Pneumocystis jirovecii pneumonia infection. Pneumocystis prophylaxis is advised in many immunocompromised populations treated with rituximab. However, the beneficial effect of pneumocystis prophylaxis in HIV-uninfected, rituximab-treated non-Hodgkin...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Kai-Che, Sy, Chenglen, Wu, Shang-Yin, Chuang, Tzu-Jung, Huang, Wei-Chun, Lai, Ping-Chin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5974272/
https://www.ncbi.nlm.nih.gov/pubmed/29844519
http://dx.doi.org/10.1038/s41598-018-26743-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5974272/
https://www.ncbi.nlm.nih.gov/pubmed/29844519
http://dx.doi.org/10.1038/s41598-018-26743-4

Ejemplares similares